Figure 6. Apln-CreER-mediated genetic ablation of tumour vessels.

(a) Schematic figure showing the strategy underlying the Apln-CreER tumour EC ablation model. Tam., tamoxifen; DTA, diphtheria toxic fragment A. (b) Picture of tumours from Apln-CreER;Rosa26RFP/DTA mice treated with tamoxifen (+Tam.) or PBS (No Tam.). (c) Quantification of tumour volume (length × width²/2 (mm³)) at various times after implantation. Student’s t-test was used to analyse differences and values are shown as means±s.e.m.; *P<0.05; n=12 for each time point. (d) Quantification of tumour volume of three different groups as indicated. wt, wild-type allele (no DTA) of the Rosa26 locus. Student’s t-test was used to analyse differences between groups, and values are shown as means±s.e.m.; *P<0.05; NS, not significant. n=4–6. (e) Whole mount view of RFP⁺ tumours. (f) Vessel detection by PECAM staining and quantification of vessel number in different groups. Student’s t-test was used to analyse differences, and values are shown as means±s.e.m.; *P<0.05; n=3–4. Scale bars, 1 mm (e), 0.5 mm (f).